RETRACTED ARTICLE: Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension

OS use over 2 years would result in lower total, drug, and hospitalization-related costs compared with OT, thus providing financial savings for payers.